Quillichew ER shortage update: What patients need to know in 2026

Quillichew ER Shortage Update for 2026

If you or your child takes Quillichew ER for ADHD, you've likely experienced the frustration of showing up at the pharmacy only to hear "we don't have it in stock." The shortage of ADHD medications has been one of the most persistent drug supply problems in the United States, and Quillichew ER continues to be affected in 2026.

Here's everything patients need to know about the current state of the Quillichew ER shortage.

Current Status: Is Quillichew ER Still in Shortage?

As of early 2026, Quillichew ER remains difficult to find at many pharmacies across the country. While Tris Pharma (the manufacturer) reports that the product is being produced and shipped, supply has not consistently kept up with demand at the pharmacy level.

The American Society of Health-System Pharmacists (ASHP) continues to list methylphenidate extended-release products among medications experiencing shortages. The primary cause cited is increased demand that has outpaced available supply.

A Timeline of the Shortage

Understanding how we got here helps explain why the shortage has lasted so long:

• 2019: FDA first reports a Quillichew ER shortage due to manufacturing delays at Pfizer/Tris Pharma
• Late 2022: The broader ADHD stimulant shortage begins. The FDA officially recognizes shortages of amphetamine and methylphenidate products
• 2023: Shortage intensifies. DEA production quotas are criticized for not keeping pace with demand. Patients report weeks-long searches for medication
• 2024: Some improvement for certain products but methylphenidate extended-release formulations remain constrained. Teva discontinues some methylphenidate CD capsule strengths
• 2025: Gradual improvements but shortages persist, especially for specialty formulations like chewable tablets and oral suspensions
• 2026: Quillichew ER continues to have intermittent availability. Supply varies widely by region and pharmacy

What's Causing the Shortage?

Several factors contribute to the ongoing shortage of Quillichew ER:

1. DEA Manufacturing Quotas

As a Schedule II controlled substance, methylphenidate is subject to annual production limits set by the DEA. These quotas are meant to prevent overproduction and diversion but have been criticized for failing to keep up with legitimate medical demand. The DEA has increased quotas in recent years, but the increases haven't fully closed the supply-demand gap.

2. Rising ADHD Diagnoses

ADHD diagnoses have increased significantly, particularly since the COVID-19 pandemic. More adults and children are being diagnosed and treated, driving up demand for all ADHD medications including Quillichew ER.

3. Limited Supply Sources

Quillichew ER is made by only one manufacturer — Tris Pharma. There is no generic version. When a single manufacturer has any production issue, patients feel the impact immediately because there's no backup supplier.

4. Insurance and Distribution Challenges

Quillichew ER is not covered by most Medicare plans and many commercial plans, which means pharmacies may stock less of it. Lower pharmacy inventory means the medication sells out faster when patients do come looking for it.

What Is the FDA Doing?

The FDA has taken several steps to address the ADHD stimulant shortage:

• Working with manufacturers to increase production capacity
• Expediting reviews of new manufacturing sites and supply agreements
• Publishing regular updates on the shortage status of affected medications
• Coordinating with the DEA on quota adjustments

However, the FDA cannot force manufacturers to produce more medication, and the DEA quota system adds another layer of complexity.

What Can Patients Do Right Now?

While waiting for the shortage to resolve, here are actionable steps:

1. Search for Quillichew ER with MedFinder: Use MedFinder to check real-time availability at pharmacies near you.
2. Plan your refills early: Don't wait until you're on your last dose. Start looking for your refill 5–7 days before you run out.
3. Expand your pharmacy search: Try independent pharmacies, hospital outpatient pharmacies, and pharmacies in nearby towns. Read our full guide to finding Quillichew ER in stock.
4. Discuss alternatives with your doctor: If you can't find Quillichew ER, your prescriber can help you switch to a similar medication temporarily. See our alternatives guide.
5. Save money while you search: The Tris Pharma Co-pay Savings Program can bring your copay down to as little as $25. Learn more in our savings guide.

When Will the Shortage End?

There is no official end date for the Quillichew ER shortage. Most healthcare industry analysts expect ADHD stimulant supply challenges to continue through at least mid-2026, with gradual improvement over time. The situation is better than it was in 2023, but it's still far from normal.

Key factors that could speed up the resolution include:

• Further increases in DEA production quotas
• New generic approvals for methylphenidate chewable formulations
• Additional manufacturing capacity coming online
• Stabilization of demand growth

Stay Informed

We'll continue to update this page as the shortage status changes. For the latest information:

• Check the FDA Drug Shortage Database
• Visit the ASHP Drug Shortage Resource Center
• Use MedFinder to track pharmacy availability in real time

For more background on why this medication is hard to find, read why Quillichew ER is so hard to find in 2026.